PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome

2023-11-07
(Press-News.org) ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, found that JAK inhibitors (JAKi) and tocilizumab elicited better response rates in VEXAS syndrome compared to other targeted therapies (Abstract #L03).

VEXAS syndrome is a rare and often fatal autoimmune condition caused by a mutation in the UBA1 gene. It is marked by widespread inflammation leading to a range of symptoms that affect the skin, lungs, blood vessels and joints. The name is an acronym for disease characteristics: vacuoles in bone marrow, E1 enzyme (the enzyme encoded by the UBA1 gene), X-linked (the UBA1 gene is located on the X chromosome), autoinflammatory and somatic (acquired after birth and not inherited).

The syndrome, first described in 2020, is often managed with high-dose corticosteroids, which have severe side effects and little high-quality data to support their role in treatment. This, and the poor five-year survival rate of VEXAS patients, led Jerome Hadjadj, M.D., Ph.D., an internist at Assistance Publique–Hôpitaux de Paris and colleagues, to conduct a retrospective multicenter study comparing the safety and efficacy of targeted therapies in patients with VEXAS syndrome.

The researchers drew their cohort of 110 predominantly male patients from the French national VEXAS registry between November 2020 and August 2023. All patients had received at least one targeted therapy, with the majority receiving JAKi ruxolitinib or the interleukin (IL)-6 inhibitor tocilizumab. Other therapies included anakinra, an IL-1 inhibitor, and tumor necrosis factor (TNF) blockers. Close to half of patients had received more than one targeted therapy. The median C-reactive protein (CRP) at the start of treatment was 39 (19-57) mg/L and the median prednisone dose was 20 (10-35) mg/day.

For the study, complete response to treatment was defined as clinical remission plus CRP less than 10 mg/L and corticosteroids less than 10 mg/day. Partial response was defined as clinical remission plus a 50% reduction in CRP and corticosteroids. No response meant continued disease activity or inflammation and/or the inability to reduce steroids.

At three months, the overall response, including complete and partial remission, was 24% with JAK inhibitors, 32% with IL-6 inhibitors, 9% with IL-1 inhibitors and 0% with TNF blockers and other targeted drugs. By six months, the overall response rate for JAK inhibitors had risen slightly to 30% and decreased slightly to 26% for IL-6 drugs. The number of complete and partial responses was similar (26% and 4% and 20% and 6%, respectively). Withdrawal of corticosteroids was also similar.

A much larger difference existed relative to discontinuation of treatment during follow-up: 28% with JAKi (median delay of 7.2 months) and 69% with IL-6 inhibitors (median delay of 5.1 months). Reasons for stopping therapy were primary or secondary failure of the treatment, serious side effects such as systemic and local reactions to the drug or death. Serious side effects were almost double with IL-6 inhibitors, but there were fewer deaths compared to JAKi.

Hadjadj, the study’s lead author, says the results were unexpected.

“It was quite surprising that the overall response at three and six months was similar between JAKi and IL-6 inhibitors because in France, a previous retrospective study showing the efficacy of JAKi in VEXAS [led] to its use as a first-line therapy. Our study shows that tocilizumab could be a good alternative, whereas other drugs are not efficient. We also showed that survival without treatment withdrawal was significantly longer with JAKi, mainly because of serious adverse events with other targeted therapies.”

The study does have limitations, Hadjadj says.

“It is a retrospective study conducted only in France, and some patients received various targeted therapies, leading to possible bias in the comparison.” He also notes that some patients were treated years before VEXAS syndrome was described.

Still, he hopes the findings of this study and future prospective studies will change clinical practice for the better.

###

About ACR Convergence

ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 240 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit https://rheumatology.org/annual-meeting, or join the conversation on Twitter by following the official hashtag (#ACR23).

About the American College of Rheumatology

Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit www.rheumatology.org.   

END



ELSE PRESS RELEASES FROM THIS DATE:

Rheumatology training program for Native American primary care physicians expands reach

2023-11-07
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, describes the expansion of a novel program to train primary care physicians (PCPs) in the diagnosis and management of rheumatoid arthritis (RA) in Native American communities that have little or no access to rheumatology care (Abstract #2455). Despite the high prevalence of RA and other rheumatologic diseases among Native Americans, many Native American communities lack adequate access to subspecialized care. As a result, responsibility for treatment has shifted to primary care providers, who often do not feel confident prescribing RA medications or ...

Study finds TNF blockers are not associated with poor pregnancy outcomes

2023-11-07
ATLANTA — According to new research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, continuing tumor necrosis factor inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy (Abstract #0477). Tumor necrosis factor (TNF) inhibitors such as adalimumab and infliximab are often prescribed for inflammatory forms of arthritis that have not improved with other treatments. Although studies suggest the drugs are safe during pregnancy, ...

Researchers identify incidence and risk factors for new-onset interstitial lung disease in systemic sclerosis

2023-11-07
ATLANTA - New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, reports the incidence and risk factors for new-onset interstitial lung disease (ILD) in previously ILD-negative systemic sclerosis patients (Abstract #1700). Interstitial lung disease is a common complication and cause of death in systemic sclerosis (SSc, scleroderma). Although the prevalence and risk factors for ILD are well known, less is known about the annual incidence and risk factors associated with the disease that occurs in patients who test negative on screening tests conducted at baseline. To answer these questions, Liubov Petelytska, ...

PET scans may predict Parkinson’s disease and Lewy body dementia in at-risk individuals

2023-11-07
In a small study, researchers at the National Institutes of Health have found that positron emission tomography (PET) scans of the heart may identify people who will go on to develop Parkinson’s disease or Lewy body dementia among those at-risk for these diseases. The findings, published in the Journal of Clinical Investigation and led by scientists at the National Institute of Neurological Disorders and Stroke (NINDS), part of NIH, may advance efforts to detect the earliest changes that years later lead to Parkinson’s disease and Lewy body dementia. In ...

Pioneering Sylvester physician elected to Society of Neuro-Oncology board

Pioneering Sylvester physician elected to Society of Neuro-Oncology board
2023-11-07
Macarena de la Fuente, MD, chief of neuro-oncology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been elected to the Society of Neuro-Oncology (SNO)’s board of directors. She will serve as the neurology representative and becomes the first Hispanic elected to the multidisciplinary board, which strives to advance brain tumor research, education and collaboration. De la Fuente has been an SNO member for over a decade and previously served as chair of the society’s ...

CAR-T cell therapy leads to long-term remission in lupus while maintaining vaccine response

2023-11-07
ATLANTA — New research at ACR Convergence 2023, the American College of Rheumatology’s annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines (Abstract #0607). Systemic lupus erythematosus (SLE, lupus) is a complex autoimmune disease marked by the production of autoantibodies to nucleic acid DNA and nuclear protein autoantigens and is associated with dysfunctional B cells. It mainly affects women and is more common and severe in people who ...

New research in JNCCN suggests a simple and inexpensive option for reducing a major chemotherapy side-effect

New research in JNCCN suggests a simple and inexpensive option for reducing a major chemotherapy side-effect
2023-11-07
PLYMOUTH MEETING, PA [November 7, 2023] — New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy. According to an analysis of 1,191 patients with early-stage breast cancer—using data collected in the SWOG S0221 study—20.7% of patients with vitamin D deficiency experienced at least a grade 3 level of chemotherapy-induced peripheral neuropathy (CIPN), compared to 14.2% of those with sufficient vitamin D levels. The researchers ...

Deep decarbonization scenarios reveal importance of accelerating zero-emission vehicle adoption

2023-11-07
The rapid adoption of zero-emission electric vehicles will move the nation close to an 80% or more drop in transportation greenhouse gas emissions by 2050 from the 2019 level according to researchers from the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL). The researchers came to that conclusion after running thousands of computer simulations on the steps needed to decarbonize passenger and freight travel, which make up the largest contributor to greenhouse gases. While they advised that “no single technology, policy, or behavioral change” is enough by itself to reach the target, eliminating tailpipe emissions would be a major factor. “There ...

SwRI-led Lucy observes first-ever contact binary orbiting an asteroid

SwRI-led Lucy observes first-ever contact binary orbiting an asteroid
2023-11-07
After the Southwest Research Institute-led Lucy mission flew past the asteroid Dinkinesh, the team discovered that it is even more “marvelous” as its newly discovered satellite is now shown to be a double-lobed moonlet. As NASA’s Lucy spacecraft continued to return data acquired during its first asteroid encounter on Nov. 1, 2023, the team discovered that Dinkinesh’s surprise satellite is itself a contact binary, made of two smaller objects touching each other. In the first image of Dinkinesh and its satellite taken at closest approach, the two lobes of the contact binary lined up, one behind the other, ...

New dates for landslides reveal past Seattle fault earthquakes

New dates for landslides reveal past Seattle fault earthquakes
2023-11-07
New maps of more than 1,000 deep-seated landslides in the Puget Lowlands of Washington State provide evidence of the last major earthquake along the Seattle Fault about 1,100 years ago—and may also hold traces of older earthquakes along the fault. Clusters of landslides offer a potential record of earthquakes, if researchers can determine when the landslides occurred. The new study published in the Bulletin of the Seismological Society of America combines information about the location of these Puget Lowlands landslides along with new dates obtained from measuring the surface roughness of the landslides. The ...

LAST 30 PRESS RELEASES:

Want to publish in Nature? Webinar with Prof. Willie Peijnenburg shares insider tips

Cataract surgery on both eyes can be carried out safely and effectively in one go

Personalized brain stimulation shows benefit for depression

AI uncovers hidden rules of some of nature’s toughest protein bonds

Innovative approach helps new mothers get hepatitis C treatment

Identifying the Interactions That Drive Cell Migration in Brain Cancer

ORNL receives 2025 SAMPE Organizational Excellence Award

University of Oklahoma researchers aim to reduce indigenous cancer disparities

Study reveals new evidence, cost savings for common treatments for opioid use disorder in mothers and infants

Research alert: Frequent cannabis users show no driving impairment after two-day break

Turbulence with a twist

Volcanic emissions of reactive sulfur gases may have shaped early mars climate, making it more hospitable to life

C-Path concludes 2025 Global Impact Conference with progress across rare diseases, neurology and pediatrics

Research exposes far-reaching toll of financial hardship on patients with cancer

The percentage of women who went without a Pap smear for cervical cancer screening increased following the COVID-19 pandemic, from 19% in 2019 to 26% in 2022

AI tools fall short in predicting suicide, study finds

Island ant communities show signs of ‘insect apocalypse’

Revealed: The long legacy of human-driven ant decline in Fiji

Analyzing impact of heat from western wildfires on air pollution in the eastern US

Inadequate regulatory protections for consumer genetic data privacy in US

Pinning down protons in water — a basic science success story

Scientists reveal how the brain uses objects to find direction

Humans sense a collaborating robot as part of their “extended” body

Nano-switch achieves first directed, gated flow of chargeless quantum information carriers

Scientist, advocate and entrepreneur Lucy Shapiro to receive Lasker-Koshland special achievement award

Creating user personas to represent the needs of dementia caregivers supporting medication management at home

UTIA participates in national study analyzing microbial communities, environmental factors impacting cotton development

Mizzou economists: 2025 farm income boosted by high cattle prices and one-time payments

What 3I/ATLAS tells us about other solar systems

University of Cincinnati allergist receives $300,000 grant to research rare esophageal disease

[Press-News.org] Study finds JAK inhibitors and tocilizumab effective in VEXAS syndrome